| 标题 |
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials |
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of oncology : official journal of the European Society for Medical Oncology 作者:Hong SD; Wang YS; Zhao HY; Zhao YY; Wang QM; et al 出版日期:2026/06/01 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)